Objective: To investigate the clinical efficacy of paroxetine combined with olanzapine in the treatment of senile schizophrenia with depression. Methods: Eighty-four elderly schizophrenic patients with depression who were admitted to our hospital from August 2016 to February 2018 were selected as research subjects and randomly divided into observation group and control group using random number table, 42 cases in each group. The control group was treated with olanzapine orally, while the observation group was treated with olanzapine and paroxetine orally. The level of homocysteine (Hcy) in the two groups was analyzed before and after treatment. The efficacy was evaluated by the Positive and Negative Symptoms Scale (PANSS) score and Hamilton Depression Scale (HAMD) score. The adverse reactions of the two groups were compared. Results: After treatment, the level of serum Hcy in the observation group was significantly lower than that in the control group (P 0.05). After?treatment, the negative factor score and PANSS score in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P 0.05). After treatment, the HAMD score of the observation group was significantly lower than that of the control group (P 0.05). Conclusion: Paroxetine combined with olanzapine has a definite clinical effect in the treatment of senile schizophrenia with depression. It can effectively reduce the level of serum Hcy, relieve the symptoms of schizophrenia, and alleviate the depressive symptoms of patients, with high safety. It?is worth promoting. doi: https://doi.org/10.12669/pjms.36.3.846 How to cite this:Wang N, Zheng N, Dong M, He J. Paroxetine combined with olanzapine in the treatment of schizophrenia. Pak J Med Sci. 2020;36(3):---------. doi: https://doi.org/10.12669/pjms.36.3.846 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
展开▼
机译：目的：探讨帕罗西汀联合奥拉汀治疗老年人精神分裂症抑郁症的临床疗效。方法：从2016年8月到2018年8月入院的抑郁症患者的八十四名老年精神分裂症患者被选为研究受试者，并使用随机编号表随机分为观察组和对照组，每组42例。对照组口服用奥氮平治疗，同时口服观察组和帕罗西汀处理。在治疗之前和之后分析了两组中的同型半胱氨酸（Hcy）的水平。通过阳性和阴性症状评分（平移）得分和汉密尔顿抑郁尺度（HAMD）得分评估疗效。比较了两组的不良反应。结果：治疗后，观察组血清Hcy水平明显低于对照组（P 0.05）。呢？治疗后，观察组的负因子评分和平底锅得分明显低于对照组，差异有统计学意义（p 0.05）。治疗后，观察组的HAMD得分明显低于对照组（P 0.05）。结论：帕罗西汀联合奥氮藻对抑郁症治疗老年精神分裂症的临床疗效。它可以有效降低血清Hcy的水平，缓解精神分裂症的症状，缓解患者的抑郁症状，高安全。它？值得促进。 doi：https://doi.org/10.12669/pjms.36.3.846如何引用这一点：王n，zheng n，dong m，他J. paroxetine联合奥拉齐滨治疗精神分裂症。 Pak J Med Sci。 2020; 36（3）：---------。 DOI：https://doi.org/10.12669/pjms.36.3.846这是一个开放的访问文章，根据Creative Commons归因许可（http://creativecommons.org/licenses/3.0）分发，只要正确引用原始工作，允许在任何媒体中不受限制使用，分发和再现。
展开▼
